ERBB2 and colorectal carcinoma: The reported ORRs (22.2–46%) and median OS (up to 15.5 months with Trastuzumab deruxtecan, Yoshino et al, 2023) compare favorably to traditional chemotherapy regimens for HER2-positive CRC, which typically yield ORRs of 10–20% and OS of 12–14 months (FOLFOX).